title: Monoclonal Antibodies for Multiple Sclerosis Treatment.
abstract: Since their introduction in medical therapy, in the last quarter of the 20th century, monoclonal antibodies have gained an increasing importance in the treatment of various diseases. Neurology has been one of the medical specialties benefiting of the therapeutic potential of these monoclonal antibodies and certain neurological conditions may now contain such drugs in their therapeutic algorithms. Multiple sclerosis is one of these diseases and, in addition to the monoclonal antibodies already licensed for clinical use, several others are in development for future utilization in this specific area. The future will certainly pass through this kind of drugs and, in this article, a review of the most relevant data related to monoclonal antibodies already in use and also in clinical development for multiple sclerosis treatment will be performed.
authors.affiliation: Institute for Biomedical Imaging and Life Sciences, CNC. IBILI Research Unit. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal. Institute for Nuclear Sciences Applied to Health (ICNAS). Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal.
authors.forename: Filipe
authors.initials: F
authors.lastname: Palavra
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized